非洛地平缓释片联合瑞舒伐他汀钙治疗对高血压患者血压变异性的影响
|
摘要
目的探讨非洛地平缓释片与瑞舒伐他汀钙相联合应用于高血压患者血压变异性的影响。方法随机选取2014年12月～2016年12月来我院诊治的186例高血压患者分为两组(对照组和试验组),对照组93例单用非洛地平缓释片进行治疗,试验组93例采用非洛地平缓释片+瑞舒伐他汀钙联合进行治疗。结果经过治疗,试验组高血压治疗有效率96.76%明显高于对照组高血压治疗有效率79.57%,同时,两组患者血脂、血压及血压变异性情况都有一定的改善,但与对照组相比,试验组有相对更好的效果,两组之间差异有统计学意义(P <0.05)。结论应用非洛地平缓释片联合瑞舒伐他汀钙,对高血压患者的血脂控制以及血压变异性改善有着明显的效果,值得进一步探究。
Objective To explorethe effect offelodipine sustained-release tablets combined with rosuvastatin calcium on blood pressure variability in patients with hypertension. Methods One hundred and eighty-six patients with hypertension who were diagnosed and treated in our hospital from December 2014 to December 2016 were randomly selected and they were divided into two groups(the control group and the experimental group).93 patients in the control group were treated by felodipine sustained-release tablets alone while the experimental group was treated by felodipine sustained-release tablets combined with rosuvastatin calcium. Results After treatment,the effective rate of treatment for hypertension in the experimental group was 96.76%,which was significantly higher than that in the control group(79.57%).At the same time,blood lipid,blood pressure and blood pressure variability were improved in both groups.However,compared with the control group,the experimental group had a relatively better effect.There were significant differences between the two groups(P < 0.05). Conclusion Felodipine sustainedrelease tablets combined with rosuvastatin calcium has significant effects on blood lipid control and improvement of blood pressure variability in patients with hypertension,which is worthy of further exploration.
Objective To explorethe effect offelodipine sustained-release tablets combined with rosuvastatin calcium on blood pressure variability in patients with hypertension. Methods One hundred and eighty-six patients with hypertension who were diagnosed and treated in our hospital from December 2014 to December 2016 were randomly selected and they were divided into two groups(the control group and the experimental group).93 patients in the control group were treated by felodipine sustained-release tablets alone while the experimental group was treated by felodipine sustained-release tablets combined with rosuvastatin calcium. Results After treatment,the effective rate of treatment for hypertension in the experimental group was 96.76%,which was significantly higher than that in the control group(79.57%).At the same time,blood lipid,blood pressure and blood pressure variability were improved in both groups.However,compared with the control group,the experimental group had a relatively better effect.There were significant differences between the two groups(P < 0.05). Conclusion Felodipine sustainedrelease tablets combined with rosuvastatin calcium has significant effects on blood lipid control and improvement of blood pressure variability in patients with hypertension,which is worthy of further exploration.
引文
[1]蓝海东.贝那普利/氨氯地平复方制剂治疗轻中度高血压患者临床效果和安全性[J].中西医结合心脑血管病杂志,2013,11(3):270-271.
[2]侯丕华,陈改玲,李格,等.老年高血压病中医临床研究进展[J].中西医结合心脑血管病杂志,2012,10(1):80-82.
[3]仇萍,姚丙南,韩世琴.老年高血压患者血压变异性与主动脉瓣钙化的关系[J].中国医药科学,2011,1(24):54-55.
[4]Ichhiara A,Kanesiro Y,Takemitsu T,et al.Ambulatory blood pressure variability and brachial-ankle pulse wave velocity in untreated hypertensive patients[J].J Hum Hypertens,2006,20(7):529-536.
[5]张清琼,张新军,常彬宾,等.老年高血压患者血压变异性与靶器官损害的相关性研究[J].四川大学学报(医学版),2011,42(2):252-255.
[6]饶继兰.氢氯噻嗪片及非洛地平缓释片治疗老年高血压病疗效观察[J].吉林医学,2011,32(23):4797-4798.
[7]蒋纪文.动态血压监测的临床应用进展[J].保健医学研究与实践,2008,5(3):80-83.
[8]Tatasciore A,R enda G,Zimarino M,et al.Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects[J].Hypertension,2007,50(2):325-332.
[9]沈燕青,徐欣,陈浩.瑞舒伐他汀联合奥美沙坦对老年高血压患者内皮功能和血压变异性的影响[J].中国老年学杂志,2016,36(3):611-613.
[10]贺文婷,欧妍,拓红梅.瑞舒伐他汀和缬沙坦对高血压患者颈动脉内膜厚度及血清炎症因子的影响[J].陕西医学杂志,2014,43(11):1531-1532.
[11]黄珏凡.瑞舒伐他汀联合坎地沙坦治疗高血压合并高脂血症的临床观察[J].包头医学院学报,2013,29(3):45-47.
[12]邵贵峰,汪茂宝,杨方成.瑞舒伐他汀联合厄贝沙坦对原发性高血压早期肾损伤患者肾脏功能及其他实验室指标的影响[J].安徽医学,2016,37(5):553-556.
[13]李雪玲,邢光,李群.贝那普利联合氨氯地平治疗原发性高血压的临床研究[J].中国医药科学,2016,6(16):57-59.
[14]李彩红.瑞舒伐他汀联合奥美沙坦酯对老年高血压患者内皮功能及血压变异性的影响[J].中国实用医药,2016,11(30):105-106.
[15]张晓君.瑞舒伐他汀钙改善老年高血压患者内皮功能及血压变异性的效果观察[J].临床研究,2018,26(6):16-18.
[16]周芳,杨洁,符炜.瑞舒伐他汀钙治疗老年冠心病合并高脂血症的效果分析[J].中外医学研究,2018,16(3):144-145.
[2]侯丕华,陈改玲,李格,等.老年高血压病中医临床研究进展[J].中西医结合心脑血管病杂志,2012,10(1):80-82.
[3]仇萍,姚丙南,韩世琴.老年高血压患者血压变异性与主动脉瓣钙化的关系[J].中国医药科学,2011,1(24):54-55.
[4]Ichhiara A,Kanesiro Y,Takemitsu T,et al.Ambulatory blood pressure variability and brachial-ankle pulse wave velocity in untreated hypertensive patients[J].J Hum Hypertens,2006,20(7):529-536.
[5]张清琼,张新军,常彬宾,等.老年高血压患者血压变异性与靶器官损害的相关性研究[J].四川大学学报(医学版),2011,42(2):252-255.
[6]饶继兰.氢氯噻嗪片及非洛地平缓释片治疗老年高血压病疗效观察[J].吉林医学,2011,32(23):4797-4798.
[7]蒋纪文.动态血压监测的临床应用进展[J].保健医学研究与实践,2008,5(3):80-83.
[8]Tatasciore A,R enda G,Zimarino M,et al.Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects[J].Hypertension,2007,50(2):325-332.
[9]沈燕青,徐欣,陈浩.瑞舒伐他汀联合奥美沙坦对老年高血压患者内皮功能和血压变异性的影响[J].中国老年学杂志,2016,36(3):611-613.
[10]贺文婷,欧妍,拓红梅.瑞舒伐他汀和缬沙坦对高血压患者颈动脉内膜厚度及血清炎症因子的影响[J].陕西医学杂志,2014,43(11):1531-1532.
[11]黄珏凡.瑞舒伐他汀联合坎地沙坦治疗高血压合并高脂血症的临床观察[J].包头医学院学报,2013,29(3):45-47.
[12]邵贵峰,汪茂宝,杨方成.瑞舒伐他汀联合厄贝沙坦对原发性高血压早期肾损伤患者肾脏功能及其他实验室指标的影响[J].安徽医学,2016,37(5):553-556.
[13]李雪玲,邢光,李群.贝那普利联合氨氯地平治疗原发性高血压的临床研究[J].中国医药科学,2016,6(16):57-59.
[14]李彩红.瑞舒伐他汀联合奥美沙坦酯对老年高血压患者内皮功能及血压变异性的影响[J].中国实用医药,2016,11(30):105-106.
[15]张晓君.瑞舒伐他汀钙改善老年高血压患者内皮功能及血压变异性的效果观察[J].临床研究,2018,26(6):16-18.
[16]周芳,杨洁,符炜.瑞舒伐他汀钙治疗老年冠心病合并高脂血症的效果分析[J].中外医学研究,2018,16(3):144-145.